All entries for: Kyverna Therapeutics

Despite having what CEO Warner Biddle called an “exceptional start” to the year, Kyverna Therapeutics had to downsize by 16% in the first quarter. As of March 31, the biotech had 119 full-time employees, as per an SEC filing. The layoffs are part of Kyverna’s effort to “streamline” its operations and support the development of its late-stage pipeline, while also extending its cash runway into 2027, the biotech announced on Tuesday, alongside its first-quarter earnings report.